We use cookies to help provide you with the best possible online experience.
By using this site, you agree that we may store and access cookies on your device. Cookie policy.
Cookie settings.
Functional Cookies
Functional Cookies are enabled by default at all times so that we can save your preferences for cookie settings and ensure site works and delivers best experience.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Ozempic, Trulicity, Bydureon
We are aware of the ongoing national shortage of glucagon like peptide-1 receptor agonists (GLP-1 RAs) used in the management of Type 2 Diabetes (T2DM). This situation is not expected to resolve until into late 2024. Supplies of some GLP-1 RA preparations may be intermittent within this time.
The injectable GLP-1 RA medication administered once weekly (Ozempic, Trulicity, Bydureon) have long-lasting effect, which means that some of the medication will still be present within the body circulation for around 3-5 weeks from the last dose taken.
We would like to encourage our patients to keep trying to obtain the current GLP-1 RA injection from their usual or any other pharmacies to maintain continuity of the treatment where possible, however, if you can’t receive your medication beyond 3 weeks’ time, please contact the practice to arrange a review.
In the meantime, if you run out of your medication, please be reassured that there should be no immediate or short term adverse effect associated with this. However, if you do feel unwell, have increased thirst, increased urination, rapid weight loss or abdominal pain please contact the surgery for urgent review.
We appreciate your understanding of a situation that is out of our control and assure you we will do our best to review you in a timely manner and ensure you receive the best possible diabetes support.
BMG Diabetes Team
Published: Jun 7, 2024